C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June


Trial Profile


Baseline demographic features and laboratory measurements by treatment allocation


Average use of study simvastatin plus ezetimibe or non-study statin and average change in plasma LDL

cholesterol from baseline, by period of follow-up


Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events


Major atherosclerotic events subdivided by type

C. Baigent, et al. Lancet 2011;Epub 9 June

Major atherosclerotic events by baseline

characteristics

χ² tests on 1 degree of freedom

are shown for heterogeneity

between rate ratios within

dichotomous categories and

for trend within other

categories. BP=blood pressure.

MDRD=Modifi ed Diet in

Renal Disease formula.17

GFR=glomerular fi ltration rate


Cause-specific and overall mortality


Cancer incidence and cancer mortality by site


Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system

C. Baigent, et al. Lancet 2011;Epub 9 June

Effects of LDL-lowering therapy

on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials

in other patients

Data from the Cholesterol Treatment Trialists’ Collaboration. χ² tests are shown for eterogeneity between rate ratios for each outcome in the four trials (4D, ALERT, AURORA, and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol.

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Documents

Transcript of C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.